
Chunxia Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7962716/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunology, Immunotherapy, 2022, 71, 1625-1631.	2.0	9
2	Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. Lung Cancer, 2022, 165, 115-123.	0.9	19
3	Three-dimensionally printed navigational template: a promising guiding approach for lung biopsy. Translational Lung Cancer Research, 2022, 11, 393-403.	1.3	3
4	HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies. Frontiers in Oncology, 2022, 12, 860313.	1.3	12
5	Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Lung Cancer, 2022, 167, 25-33.	0.9	9
6	Low baseline plasma <scp>PCSK9</scp> level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 353-360.	0.8	9
7	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. Translational Lung Cancer Research, 2021, 10, 3929-3942.	1.3	6
8	The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1149-1158.	1.3	17
9	HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. Lung Cancer, 2020, 147, 99-105.	0.9	21
10	Clinical features and therapeutic options in nonâ€small cell lung cancer patients with concomitant mutations of <i>EGFR</i> , <i>ALK</i> , <i>ROS1</i> , <i>KRAS</i> or <i>BRAF</i> . Cancer Medicine, 2019, 8, 2858-2866.	1.3	59
11	Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Clinical Cancer Research, 2019, 25, 3486-3494.	3.2	56
12	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations – Still a daily challenge. European Journal of Cancer, 2017, 83, 266-278.	1.3	22
13	Correlation of long non-coding RNA <i>H19</i> expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma. Oncotarget, 2017, 8, 2558-2567.	0.8	70
14	Osimertinib for EGFR T790M positive non-small cell lung cancer—making it happen, turning good idea into great results. Translational Cancer Research, 2017, 6, S494-S497.	0.4	0
15	Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients. Translational Oncology, 2014, 7, 341-348.	1.7	68